ECSP099516A - Composición suplementaria nutricional para el tratamiento de enfermedades oculares - Google Patents

Composición suplementaria nutricional para el tratamiento de enfermedades oculares

Info

Publication number
ECSP099516A
ECSP099516A EC2009009516A ECSP099516A ECSP099516A EC SP099516 A ECSP099516 A EC SP099516A EC 2009009516 A EC2009009516 A EC 2009009516A EC SP099516 A ECSP099516 A EC SP099516A EC SP099516 A ECSP099516 A EC SP099516A
Authority
EC
Ecuador
Prior art keywords
treatment
nutritional composition
eye diseases
supplementary nutritional
supplementary
Prior art date
Application number
EC2009009516A
Other languages
English (en)
Inventor
Georg Ludwig Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024441&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099516(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP099516A publication Critical patent/ECSP099516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a un antioxidante y composición de suplemento de luteína, la cual entre otras cosas, reduce la pérdida de agudeza visual reduciendo el riesgo de desarrollar degeneración macular de etapa tardía o relacionada con la edad, en personas con degeneración macular relacionada con la edad temprana.
EC2009009516A 2006-12-15 2009-07-15 Composición suplementaria nutricional para el tratamiento de enfermedades oculares ECSP099516A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126261A EP1932521A1 (en) 2006-12-15 2006-12-15 Nutritional supplement composition for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
ECSP099516A true ECSP099516A (es) 2009-08-28

Family

ID=38024441

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009516A ECSP099516A (es) 2006-12-15 2009-07-15 Composición suplementaria nutricional para el tratamiento de enfermedades oculares

Country Status (22)

Country Link
US (1) US20100028459A1 (es)
EP (2) EP1932521A1 (es)
JP (1) JP2010513248A (es)
KR (1) KR20090089473A (es)
CN (1) CN101557807A (es)
AR (1) AR064332A1 (es)
AU (1) AU2007331432A1 (es)
BR (1) BRPI0720046A2 (es)
CA (1) CA2672013A1 (es)
CL (1) CL2007003630A1 (es)
CO (1) CO6220929A2 (es)
EC (1) ECSP099516A (es)
GT (1) GT200900161A (es)
MA (1) MA30994B1 (es)
MX (1) MX2009006306A (es)
NO (1) NO20092633L (es)
PE (1) PE20081580A1 (es)
RU (1) RU2009126735A (es)
TN (1) TN2009000241A1 (es)
TW (1) TW200843725A (es)
WO (1) WO2008071775A1 (es)
ZA (1) ZA200903862B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389504B2 (en) * 2008-05-08 2013-03-05 Mead Johnson Nutrition Company Prenatal dietary supplement
WO2010074940A1 (en) * 2008-12-23 2010-07-01 Alcon Research, Ltd. Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
CN103796717A (zh) * 2011-07-07 2014-05-14 霍华德基金会控股有限公司 视觉功效和/或黄斑色素沉着的改善或与之相关的改善
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
JP2016508955A (ja) * 2011-09-12 2016-03-24 ジョルジオ タソスＧＥＯＲＧＩＯＵ， Ｔａｓｓｏｓ 疾病治療用オメガ脂肪酸の使用
CN102538980A (zh) * 2012-01-12 2012-07-04 杭州美盛红外光电技术有限公司 热像装置和热像拍摄方法
JP2016185939A (ja) * 2015-03-27 2016-10-27 ロート製薬株式会社 経口組成物
JP2016190829A (ja) * 2015-03-31 2016-11-10 ウィルファーム株式会社 活性型ｄｈａを含む製剤、強化食品、サプリメント並びに化粧品
JP6056114B2 (ja) * 2015-05-30 2017-01-11 富田製薬株式会社 油状物質含有粉末組成物
CN108208804A (zh) * 2018-01-05 2018-06-29 美博迪尔（北京）生物科技有限公司 一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法
CN108096288A (zh) * 2018-01-16 2018-06-01 南京圣诺生物科技实业有限公司 护眼片及其制备方法和应用
EP4117652A1 (en) * 2020-03-11 2023-01-18 Bausch + Lomb Ireland Limited Compositions and methods for eye health comprising very long chain fatty acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
US20050112210A1 (en) * 2003-09-12 2005-05-26 Terry Grossman Eye nutritional supplement
WO2005110375A1 (en) * 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
DE202005012984U1 (de) * 2005-08-17 2005-11-24 W & B Pharmamarken Gmbh Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
EP1962618A2 (en) * 2005-12-20 2008-09-03 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision

Also Published As

Publication number Publication date
MA30994B1 (fr) 2009-12-01
TN2009000241A1 (en) 2010-10-18
TW200843725A (en) 2008-11-16
PE20081580A1 (es) 2009-01-01
BRPI0720046A2 (pt) 2013-12-24
EP2094252A1 (en) 2009-09-02
CA2672013A1 (en) 2008-06-19
JP2010513248A (ja) 2010-04-30
MX2009006306A (es) 2009-06-23
CN101557807A (zh) 2009-10-14
EP1932521A1 (en) 2008-06-18
RU2009126735A (ru) 2011-01-20
CL2007003630A1 (es) 2008-08-08
CO6220929A2 (es) 2010-11-19
ZA200903862B (en) 2010-05-26
KR20090089473A (ko) 2009-08-21
WO2008071775A1 (en) 2008-06-19
GT200900161A (es) 2009-11-30
AR064332A1 (es) 2009-04-01
US20100028459A1 (en) 2010-02-04
NO20092633L (no) 2009-07-10
AU2007331432A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
ECSP099516A (es) Composición suplementaria nutricional para el tratamiento de enfermedades oculares
MX2009006342A (es) Composicion de complemento alimenticio para tratamiento de enfermedades oculares.
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
BRPI0518289A2 (pt) mÉtodos e composiÇÕes para o tratamento de desordens oculares
WO2007076416A3 (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
UA95105C2 (ru) Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
EP2781899A3 (en) Multi-band color vision filters
GB201305581D0 (en) Composition and method of manufacture
WO2008094825A3 (en) Compositions and methods for maintaining, strengthening, improving or promoting eye health
GEP20094644B (en) Retinyl derivatives, compositions thereof and assays for treating retinol-related diseases
WO2009111603A3 (en) Deitary supplement for eye health
TWI319708B (en) Methods and compositions for altering cell fuction
BR112014007741A2 (pt) bebidas nutritivas
CO6761363A2 (es) Masa de chocolate
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
ECSP15034601A (es) Composiciones nutricionales que contienen treonato de magnesio, y sus usos
ECSP13012799A (es) Uso de composiciones nutricionales que incluyen lactoferrinas para mejorar la resistencia a enfermedades y condiciones
AR066732A1 (es) Lentes disenadas para el tratamiento de la astenopia causada por defectos visuales
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
ECSP13012798A (es) Método para inhibir patógenos usando una composición nutricional
EP2083841A4 (en) TREATMENT OF MACULAR DEGENERATION FROM AGING AND OTHER OCULAR DISEASES
WO2015009829A3 (en) Enhancement of osteogenic potential of bone grafts
CL2009000230A1 (es) Composicion de suplemento nutricional o dietetico que comprende vitamina c, vitamina e, luteina, zinc, acidos grasos omega 3 y cobre; metodo de fabricacion; uso para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad y retinopatia diabetica.
WO2014193632A3 (en) Single chain intrabodies that alter huntingtin mutant degradation